OncoMatch/Clinical Trials/NCT06976892
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Is NCT06976892 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for high grade serous ovarian cancer.
Treatment: Dose Level 2 (starting dose) · Dose Level 1 · Dose Level -1 · Dose Level 3 · Maximum Tolerated Dose — Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Idetrexed has been designed to selectively target cancer cells that have a protein called folate receptor on the surface of cancer cells. Thymidylate synthase is key to cancer cells for creating new DNA when they multiply. Blocking the action of thymidylate synthase with a drug like Idetrexed may therefore stop cancers from growing by damaging DNA in cancer cells. Olaparib is a type of drug called a "PARP inhibitor". It prevents cells repairing DNA damage. This leads to cells dying. Combining Idetrexed and olaparib should increase the number of cancer cells dying, especially those cells that have a lot of folate receptors. Cancer cells with a high number of folate receptors should be targeted more than normal healthy cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: FOLR1 medium to high expression (medium to high)
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: radiotherapy
Exception: palliative reasons
Cannot have received: endocrine therapy
Cannot have received: immunotherapy
Cannot have received: chemotherapy
Cannot have received: investigational medicinal products
Lab requirements
Blood counts
haematological indices within protocol ranges
Kidney function
biochemical indices within protocol ranges
Liver function
biochemical indices within protocol ranges
Cardiac function
Normal (no clinically significant abnormalities) 12-lead ECG, QTcF interval <470 ms
Haematological and biochemical indices within the ranges shown in Protocol section 4.1.1). Normal (no clinically significant abnormalities) 12-lead ECG, QTcF interval <470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06976892 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, endocrine therapy, immunotherapy disqualifies patients from enrollment.
Does this trial require FOLR1?
Yes, FOLR1 medium to high expression is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify